Abstract #4831

Does the timing of immunotherapy with stereotactic radiosurgery affect the outcome of patients with brain metastases?

Endre Grøvik¹, Line Brennhaug Nilsen¹, Ingrid Digernes¹, Cathrine Saxhaug¹, Anna Latysheva¹, Oliver Geier¹, Birger Breivik², Dag Ottar Sætre³, Kari Dolven Jacobsen¹, Åslaug Helland¹, and Kyrre Eeg Emblem¹

¹Oslo University Hospital, Oslo, Norway, ²Hospital of Southern Norway, Kristiansand, Norway, ³Østfold Hospital Trust, Kalnes, Norway

The introduction of immunotherapy (IMTx) has led to a paradigm shift in the treatment of patients with metastatic cancer. Particular interest has been directed towards combining IMTx with stereotactic radiosurgery (SRS) to improve treatment response. Lately, studies have indicated that the timing of IMTx with SRS may be crucial for the patient outcome, suggesting that there is a window of opportunity to induce an optimal synergy between irradiation and immune agents. To this end, this work investigates whether the timing of IMTx with SRS affects the outcome of patients with brain metastases.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.